Gronghui May 15 丨 Haisike (002653)(00265350freespinsbookofdead.SZ) announced that the company's subsidiary, Xizang Haisike Pharmaceutical Co., Ltd., recently received a notice from the State Drug Administration50freespinsbookofdead"Acceptance Notice". HSK39004 is independently developed by the company50freespinsbookofdeadA new targeted small molecule inhibitor with independent intellectual property rights is clinically proposed for the treatment of obstructive pulmonary diseases (such as COPD and asthma) characterized by airway resistance. According to the provisions on the registration classification of chemical drugs in the Notice of the State Food and Drug Administration on Issuing the "Requirements for Registration Classification and Application Materials of Chemical Drugs"(No. 44 of 2020), this product belongs to Class 1 chemical drugs.

Preclinical study results show that HSK39004 shows significant airway relaxation and anti-inflammatory effects in isolated tracheal rings and in vivo disease models, and has good safety. It is a small molecule obstructive pulmonary disease treatment with great development potential. Drug, is expected to provide a new treatment option for patients with obstructive pulmonary diseases such as COPD and asthma.